Camilla Veronica Simpson

Camilla Veronica Simpson serves as the Chief Executive Officer at Zehna Therapeutics Inc., a preclinical stage biotech company dedicated to developing small molecule inhibitors for chronic kidney disease and cardiovascular disease. With extensive experience in the biotech sector, Camilla holds multiple board positions, including Independent Board Member roles at GRI Bio, Inc., Dyve Biosciences, and Spruce Biosciences, and is the Managing Member and President of Rare Strategic, LLC, where strategic advisory services are provided to early-stage companies. Previous roles include senior leadership positions at BioMarin Pharmaceutical Inc. and Shire Pharmaceuticals, focusing on global product strategy, regulatory affairs, and early development operations. Camilla's academic qualifications include a BSc in Science from the University of Galway, an MSc with Distinction in Analytical Chemistry from Birkbeck, University of London, and a BSc Hons in Chemistry from Kingston University.